The company closed its third quarter reporting Humira sales of $4,060, +11.3% on a year over year basis and -2.2% from the previous quarter of 2016. In the third quarter of 2016, the sale of Humira represented approximately 63.6% of AbbVies total adjusted net revenues. The medication, introduced to the market in January 2003, is approved for use in North America, the European Union and is also approved for more than 60 other markets, including Japan, China, Brazil and Australia. Since the patent covering adalimumab (brand name Humira), the human monoclonal antibody that recognizes TNF-alpha as antigen, is expected to expire in the U.S. in December 2016 and in the majority of EU countries in October 2018, investors are concerned that competition from biosimilars (Amgens Amjevita, recently approved by FDA, and Boehringer Ingelheim’s BI 695501 ) could blow a huge hole in the companys revenue. Investors rightly see that AbbVie has a dilemma because the company can generate plenty of cash to sustain the dividend growth (the current dividend yield is 4.59%) from the sale of Humira. However, shareholders should not see Amgen ( NASDAQ:AMGN ) and Boehringer Ingelheims products as a threat to the companys revenues because the two medications are biosimilar to Humira and not interchangeable products. Being a biosimilar product, it will take some time before the competing medications become marketable products that may subtract from AbbVies Humira market share. Furthermore, AbbVie CEO Rick Gonzalez has promised that the company can prevent biosimilar competition until 2022.
For the original version including any supplementary images or video, visit http://www.gurufocus.com/news/456754/abbvie-reports-3rd-quarter-results
Some.f these drugs may increase the risk of having cancer. Retinitis affects the back of the eye. Philadelphia, Pa: Lippincott; 2008. The Best Questions For Details For Retinal Detachment | Charles Rivera TravelDoctoors don’t often prescribe these, but you may take them if steroids haven’t helped. occult Immunol inflame. 2004;123:203-14. She received her BA from Pomona College in Claremont, A, and her MD from the University of Colorado in Denver, CO. It is most common in young and middle-aged people. http://advisingeyedoc.firehousepub.net/2016/11/04/a-quick-a-z-on-rudimentary-strategies-of-laser-eye-surgery/This involves inflammation in the front part of the eye. What Is non-infectious Uveitis? Carr Odin Allergy Cain Immunol. 2014 Oct. 14 5:485-9. The most common side effects noted during those studies were cataract progression, increased intra ocular pressure, procedural complications and eye pain. Symptoms of uveitis include eye pain, or discomfort, eye redness, blurred vision, and sensitivity to light photo phobia . It is a treatable condition; however, without proper treatment, it can lead to much more serious conditions such as glaucoma, cataracts, or retinal enema. Uveitis disrupts vision by primarily causing problems with the lens, retina, optic nerve, and vitreous see diagram: Lens: Transparent tissue that allows light into the eye.